Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -25.06
- Piotroski Score 2.00
- Grade Hold
- Symbol (BIOC)
- Company Biocept, Inc.
- Price $0.43
- Changes Percentage (0%)
- Change -$0
- Day Low $0.43
- Day High $0.49
- Year High $0.49
Biocept, Inc., a molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating cell-free tumor DNA and RNA assays utilizing a standard blood sample. Its cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring to identify resistance mechanisms. The company offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer (NSCLC), gastric cancer, colorectal cancer, prostate cancer, pancreaticobiliary cancer, and ovarian cancer. It also provides cerebrospinal fluid tumor cell and ctDNA and ctRNA testing services to medical oncologists, neuro-oncologists, surgical oncologists, urologists, pulmonologists, pathologists, and other physicians; clinical trial and research services to pharmaceutical companies, biopharmaceutical companies and clinical research organizations; and RT-PCR testing services for COVID-19. The company has a collaboration with CLEARED4 to develop a system for tracking and managing COVID-19 testing requirements and test results for its customers; and with Protean BioDiagnostics, Inc. to research the ability of its Target Selector molecular assay to determine EGFR status in NSCLC patients. Biocept, Inc. was incorporated in 1997 and is headquartered in San Diego, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 05/08/2024
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Buy
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$48.17
- Trailing P/E Ratio -0.01
- Forward P/E Ratio -0.01
- P/E Growth -0.01
- Net Income $-32,087,000
Income Statement
Quarterly
Annual
Latest News of BIOC
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
BioCryst Secures Major US Health Department Influenza Drug Deal
BioCryst Pharmaceuticals secured a $69 million contract with the U.S. Department of Health and Human Services to supply RAPIVAB® for influenza treatment over five years. The agreement aims to strengt...
By Yahoo! Finance | 5 days ago -
Bioceres Crop Solutions Corp. (BIOX): Hedge Funds Are Bearish On This Affordable Stock Under $40
An analysis of Bioceres Crop Solutions Corp. (NASDAQ:BIOX) among the worst performing affordable stocks under $40 post-Fed rate cut. The company aims for carbon-neutral farming and showed growth despi...
By Yahoo! Finance | 1 week ago -
Things Look Grim For Bioceres Crop Solutions Corp. (NASDAQ:BIOX) After Today's Downgrade
Analysts have revised Bioceres Crop Solutions Corp.'s forecasts negatively, showing pessimism towards the company's near-term performance. Revenue and earnings estimates were slashed, with a 29% price...
By Yahoo! Finance | 3 weeks ago
